| Trial ID: | L4742 |
| Source ID: | NCT02824003
|
| Associated Drug: |
Isis-Gcgrrx
|
| Title: |
Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: ISIS-GCGRRx|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in fasting hepatic glycogen content, Change from Baseline, Week 14|Change in fasting hepatic lipid content, Change from Baseline, Week 14 | Secondary: Safety and Tolerability will be assessed by determining the incidence, severity, dose relationship of adverse effects, and changes in laboratory evaluations, Safety results in patients dosed with ISIS 449884 will be compared with those from patients dosed with placebo, 38 weeks
|
| Sponsor/Collaborators: |
Sponsor: Ionis Pharmaceuticals, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2016-04
|
| Completion Date: |
2017-05-22
|
| Results First Posted: |
|
| Last Update Posted: |
2018-05-08
|
| Locations: |
Ionis Investigator Site, Vienna, A-1130, Austria
|
| URL: |
https://clinicaltrials.gov/show/NCT02824003
|
